Fusion Pharmaceuticals Appoints Maria Stahl as Chief Legal Officer

Rhea-AI Summary

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced the appointment of Maria Stahl as the new chief legal officer, effective immediately. With extensive legal experience in the biopharmaceutical industry, Stahl's leadership is expected to aid in advancing the company's lead candidate and expanding its development pipeline. CEO John Valliant emphasized the importance of her strategic guidance during this critical growth phase. Fusion's lead program, FPI-1434, is currently undergoing a Phase 1 clinical trial, reflecting the company’s focus on developing next-generation radiopharmaceuticals.

Positive

• Appointment of Maria Stahl as chief legal officer expected to strengthen legal and operational strategy.
• Stahl's extensive experience in biopharmaceuticals may enhance Fusion's development pipeline.
• Leadership change comes at a pivotal growth phase for the company.

Negative

• None.

HAMILTON, ON and BOSTON, Sept. 29, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Maria Stahl as chief legal officer.

"Maria brings to Fusion a breadth of legal and operational experience within the biopharmaceutical industry which will be invaluable during this pivotal phase of our company's growth," said Chief Executive Officer John Valliant, Ph.D. "Maria will provide important strategic guidance and legal counsel as we advance our lead candidate and seek to expand our development pipeline. We are excited to welcome her to Fusion's leadership team."  

Prior to joining Fusion, Ms. Stahl held executive leadership roles at Tetraphase Pharmaceuticals, including chief business officer and general counsel. Before joining Tetraphase, Ms. Stahl was the senior vice president, general counsel of Idenix Pharmaceuticals. Ms. Stahl began her career with the law firm Wilmer Cutler Pickering Hale and Dorr LLP. Ms. Stahl holds a bachelor of arts from Providence College and a juris doctorate from Yale Law School.

"Fusion has an opportunity to capitalize on a platform technology and deep radiopharmaceutical expertise during a time of significant momentum in the space," said Ms. Stahl. "I am excited to join the team and look forward to working towards our goal to deliver novel cancer therapies to patients."

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial.

View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-appoints-maria-stahl-as-chief-legal-officer-301140310.html

SOURCE Fusion Pharmaceuticals Inc.

FAQ

What is Fusion Pharmaceuticals' recent management change?

Fusion Pharmaceuticals appointed Maria Stahl as the chief legal officer.

What experience does Maria Stahl bring to Fusion Pharmaceuticals?

Maria Stahl brings extensive legal and operational experience from her previous roles at Tetraphase Pharmaceuticals and Idenix Pharmaceuticals.

How might Maria Stahl's appointment impact Fusion Pharmaceuticals?

Her legal expertise is expected to provide strategic guidance as Fusion advances its lead candidate and expands its development pipeline.

What is the status of Fusion Pharmaceuticals' lead program FPI-1434?

FPI-1434 is currently in a Phase 1 clinical trial.

When was Maria Stahl appointed chief legal officer of Fusion Pharmaceuticals?

Maria Stahl was appointed on September 29, 2020.